Novel tuberculosis vaccine shows promising immunogenicity and safety profile
Vaccine is produced by SSI and contains Intercell's adjuvant IC31
Statens Serum Institut (SSI) and Intercell announced that their collaborative novel tuberculosis (TB) vaccine is safe and very immunogenic in healthy individuals in a phase I clinical trial. Based on these results the partners will initiate a clinical trial with latent TB-infected and BCGvaccinated individuals later in 2007.
The new H1 vaccine from SSI is a recombinant subunit vaccine based on two important TB antigens resulting from SSI's research pipeline combined with Intercell's proprietary adjuvant IC31(TM). The phase I clinical trial was performed at the Department of Infectious Diseases (headed by Prof. Jaap van Dissel) at Leiden University Medical Center in the Netherlands and was supported by the European Union-funded program "TB-VAC".
H1 is a TB vaccine antigen in which two immuno dominant TB antigens (Ag85B and ESAT6) are fused together by recombinant technology and produced as a poly-protein. IC31TM is an adjuvant inducing both T-cell and B-cell responses with a unique synthetic formulation which combines the immunostimulating properties of an anti-microbial peptide, KLK, and an immunostimulatory oligodeoxynucleotide, ODN1a. The two component solution can be simply mixed with antigens, no conjugation is required.
Other news from the department research and development
